Literature DB >> 19950271

Interferon-alpha mediates suppression of C-reactive protein: explanation for muted C-reactive protein response in lupus flares?

Helena Enocsson1, Christopher Sjöwall, Thomas Skogh, Maija-Leena Eloranta, Lars Rönnblom, Jonas Wetterö.   

Abstract

OBJECTIVE: C-reactive protein (CRP) is synthesized by hepatocytes in response to interleukin-6 (IL-6) during inflammation. Despite raised IL-6 levels and extensive systemic inflammation, serum CRP levels remain low during most viral infections and disease flares of systemic lupus erythematosus (SLE). Because both viral infections and SLE are characterized by high levels of interferon-alpha (IFNalpha), the aim of this study was to determine whether this cytokine can inhibit the induction of CRP.
METHODS: The interference of all 12 IFNalpha subtypes with CRP promoter activity induced by IL-6 and IL-1beta was studied in a CRP promoter- and luciferase reporter-transfected human hepatoma cell line, Hep-G2. CRP secretion by primary human hepatocytes was analyzed by enzyme-linked immunosorbent assay.
RESULTS: CRP promoter activity was inhibited by all single IFNalpha subtypes, as well as by 2 different mixtures of biologically relevant IFNalpha subtypes. The most prominent effect was seen using a leukocyte-produced mixture of IFNalpha (56% inhibition at 1,000 IU/ml). The inhibitory effect of IFNalpha was confirmed in primary human hepatocytes. CRP promoter inhibition was dose dependent and mediated via the type I IFN receptor. Transferrin production and Hep-G2 proliferation/viability were not affected by IFNalpha.
CONCLUSION: The current study demonstrates that IFNalpha is an inhibitor of CRP promoter activity and CRP secretion. This finding concords with previous observations of up-regulated IFNalpha and a muted CRP response during SLE disease flares. Given the fundamental role of both IFNalpha and CRP in the immune response, our results are of importance for understanding the pathogenesis of SLE and may also contribute to understanding the differences in the CRP response between viral and bacterial infections.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19950271     DOI: 10.1002/art.25042

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  33 in total

Review 1.  A novel pathogenetic concept-antiviral immunity in lupus nephritis.

Authors:  Adriana Migliorini; Hans-Joachim Anders
Journal:  Nat Rev Nephrol       Date:  2012-01-17       Impact factor: 28.314

2.  Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma.

Authors:  Ahmad A Tarhini; John Cherian; Stergios J Moschos; Hussein A Tawbi; Yongli Shuai; William E Gooding; Cindy Sander; John M Kirkwood
Journal:  J Clin Oncol       Date:  2011-12-19       Impact factor: 44.544

3.  Pulmonary impairment, not muscle injury, is associated with elevated ESR in the idiopathic inflammatory myopathies.

Authors:  Jin Kyun Park; Allan C Gelber; Michael George; Sonye K Danoff; Marzouq A Qubti; Lisa Christopher-Stine
Journal:  Rheumatology (Oxford)       Date:  2013-04-24       Impact factor: 7.580

Review 4.  C-reactive protein in rheumatology: biology and genetics.

Authors:  Benjamin Rhodes; Barbara G Fürnrohr; Timothy J Vyse
Journal:  Nat Rev Rheumatol       Date:  2011-04-05       Impact factor: 20.543

5.  Interferon-α coincides with suppressed levels of pentraxin-3 (PTX3) in systemic lupus erythematosus and regulates leucocyte PTX3 in vitro.

Authors:  L Wirestam; H Enocsson; T Skogh; M L Eloranta; L Rönnblom; C Sjöwall; J Wetterö
Journal:  Clin Exp Immunol       Date:  2017-03-31       Impact factor: 4.330

6.  C-reactive protein +1444CT (rs1130864) genetic polymorphism is associated with the susceptibility to systemic lupus erythematosus and C-reactive protein levels.

Authors:  Francieli Delongui; Marcell Allyson Batisti Lozovoy; Tatiana Mayiumi Veiga Iriyoda; Neide Tomimura Costa; Nicole Perugini Stadtlober; Daniela Frizon Alfieri; Tamires Flauzino; Isaias Dichi; Andréa Name Colado Simão; Edna Maria Vissoci Reiche
Journal:  Clin Rheumatol       Date:  2017-06-01       Impact factor: 2.980

7.  The ratio of erythrocyte sedimentation rate to C-reactive protein is useful in distinguishing infection from flare in systemic lupus erythematosus patients presenting with fever.

Authors:  E Littlejohn; W Marder; E Lewis; S Francis; J Jackish; W J McCune; E C Somers
Journal:  Lupus       Date:  2018-03-16       Impact factor: 2.911

8.  Elevated interleukin 8 and T-helper 1 and T-helper 17 cytokine levels prior to antiretroviral therapy in participants who developed immune reconstitution inflammatory syndrome during ACTG A5164.

Authors:  Philip M Grant; Lauren Komarow; Michael M Lederman; Savita Pahwa; Andrew R Zolopa; Janet Andersen; David M Asmuth; Sridevi Devaraj; Richard B Pollard; Aaron Richterman; Sudheesh Kanthikeel; Irini Sereti
Journal:  J Infect Dis       Date:  2012-09-21       Impact factor: 5.226

9.  C-reactive protein inhibits plasmacytoid dendritic cell interferon responses to autoantibody immune complexes.

Authors:  Carolyn Mold; Terry W Du Clos
Journal:  Arthritis Rheum       Date:  2013-07

10.  Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death.

Authors:  David R Boulware; Katherine Huppler Hullsiek; Camille E Puronen; Adam Rupert; Jason V Baker; Martyn A French; Paul R Bohjanen; Richard M Novak; James D Neaton; Irini Sereti
Journal:  J Infect Dis       Date:  2011-06-01       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.